BioSpace News Archive

The global dental practice management software is anticipated to witness a remarkable growth in the coming years owing to the increasing number of dental problems as per the reports of the Transparency Market Research states.

According to the recent report by Transparency Market Research, the global autoimmune disease diagnostics market has a highly consolidated scenario.

Lyophilization has been popularly employed by the pharmaceuticals industry in parenteral product development.

Many patients who undergo dialysis often do not have a suitable vein from which impure blood can be removed.

MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”) has secured its first European white-label cannabis supply agreement with Therismos Limited

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan flufenamide) have been selected for presentation at the American Association for Cancer Research (AACR). The poster presentations are now available online. Melflufen is a first-in-clas

Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation. “We are excited to en

China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced financial results for the quarter ended March 31, 2020 . First Quarter Highlights Revenue decreased

Correvio Pharma Corp. (“Correvio” or the “Company”) (NASDAQ: CORV) (TSX: CORV), today announced the results of voting on matters considered at its annual general and special meeting (the “Meeting”) of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the “Securityholders”) which took place in a virtual format earlier today.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will take place from June 22 to 24, 2020. Session information is available online via the Annual Meeting Itinerary